Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia 1Hodgkin Disease 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 34Cisplatin 34Radiotherapy 30Oxaliplatin 30Paclitaxel 22pembrolizumab 20Irinotecan 20Docetaxel 20Leucovorin 19Capecitabine 16Cetuximab 11Carboplatin 11Bevacizumab 11Radiation 10Surgical Procedures, Operative 9Trastuzumab 8Panitumumab 6Epirubicin 6Neoadjuvant Therapy 5Esophagectomy 4Erlotinib Hydrochloride 4Chemotherapy, Adjuvant 4tisotumab vedotin 3durvalumab 3Sunitinib 3Microarray Analysis 3Immunohistochemistry 3Gene Expression Profiling 3Gemcitabine 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Esophageal Neoplasms × pegylated granulocyte colony-stimulating factor, human × Clear all
NCT00069953 2017-02-17

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Radiation Therapy Oncology Group

Phase 2 Completed
43 enrolled 5 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡